Amgen DCF Analysis Highlights 24% Overvaluation, Reinforcing Sell Thesis

What happened

A July 13, 2026 DCF analysis from GuruFocus pegs Amgen's intrinsic value at $292 per share, versus a market price of $363, implying a 24% overvaluation. This aligns with the most recent DeepValue master report that assigned a 'Potential Sell' rating with a $295 attractive entry and $370 trim threshold. The report's base-case scenario values the stock at $340, but the higher market price signals that investors are already pricing in optimistic assumptions for MariTide and Horizon asset growth. Meanwhile, the master report highlights structural headwinds: accelerating price erosion on Enbrel, IRA-driven profit compression on Otezla, imminent biosimilar competition for Prolia/XGEVA, and unresolved IRS tax exposure. The DCF analysis adds a fresh data point suggesting the risk/reward skew remains negative at current levels, especially as the primary upside catalyst—MariTide Phase 3 data—is still months away.

Implication

The DCF reinforces the view that Amgen's current price embeds overly optimistic expectations for pipeline success and portfolio growth, with limited margin of safety against policy and competitive risks. Management's guidance and recent execution have been solid, but the structural erosion on legacy drugs is accelerating and will likely outweigh growth from newer assets in the near term. The obesity story provides optionality, but the market is pricing in a high probability of success that leaves little room for disappointment. Given the stock's 24% premium to DCF value and proximity to the master report's trim level, the prudent action is to reduce positions on any strength above $370. A more attractive entry would be near $295, where the bear-case scenario of $270 provides a better risk/reward.

Thesis delta

The primary shift is that the market has pushed Amgen's price further above intrinsic value estimates, moving from a modest premium in February 2026 ($339 vs. base case $340) to a more pronounced overvaluation ($363 vs. DCF $292). This increases the likelihood of a mean-reverting pullback, especially if upcoming MariTide or Horizon updates fail to exceed already high expectations. The fundamental outlook has not changed, but the valuation cushion has narrowed, making the sell thesis more compelling in the near term.